Analysts Expect PolarityTE, Inc. (NASDAQ:PTE) Will Post Quarterly Sales of $850,000.00

Equities analysts predict that PolarityTE, Inc. (NASDAQ:PTEGet Rating) will announce sales of $850,000.00 for the current quarter, Zacks reports. Two analysts have issued estimates for PolarityTE’s earnings, with estimates ranging from $800,000.00 to $900,000.00. PolarityTE reported sales of $4.71 million during the same quarter last year, which indicates a negative year over year growth rate of 82%. The company is scheduled to report its next earnings results before the market opens on Monday, January 1st.

On average, analysts expect that PolarityTE will report full year sales of $3.20 million for the current financial year, with estimates ranging from $2.80 million to $3.60 million. For the next fiscal year, analysts anticipate that the firm will post sales of $3.80 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that follow PolarityTE.

PolarityTE (NASDAQ:PTEGet Rating) last posted its quarterly earnings results on Wednesday, March 30th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01). PolarityTE had a negative net margin of 321.00% and a negative return on equity of 116.16%. The firm had revenue of $1.04 million during the quarter, compared to analyst estimates of $0.94 million. During the same period last year, the company earned ($0.21) EPS.

PTE has been the subject of a number of recent research reports. Zacks Investment Research cut PolarityTE from a “buy” rating to a “hold” rating in a report on Thursday, January 13th. Cantor Fitzgerald cut PolarityTE from an “overweight” rating to a “neutral” rating in a report on Wednesday, March 30th.

Shares of PTE opened at $0.13 on Thursday. PolarityTE has a 1 year low of $0.13 and a 1 year high of $1.26. The stock has a 50 day simple moving average of $0.26 and a 200-day simple moving average of $0.43. The stock has a market cap of $11.46 million, a PE ratio of -0.32 and a beta of 1.13.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Marshall Wace North America L.P. bought a new stake in PolarityTE during the 1st quarter worth approximately $73,000. Marshall Wace LLP bought a new position in PolarityTE in the 1st quarter valued at $126,000. First Republic Investment Management Inc. boosted its position in PolarityTE by 79.1% in the 3rd quarter. First Republic Investment Management Inc. now owns 56,600 shares of the company’s stock valued at $37,000 after buying an additional 25,000 shares during the last quarter. HighTower Advisors LLC bought a new position in PolarityTE in the 4th quarter valued at $35,000. Finally, D. E. Shaw & Co. Inc. boosted its position in PolarityTE by 188.6% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 76,867 shares of the company’s stock valued at $45,000 after buying an additional 50,236 shares during the last quarter. Institutional investors and hedge funds own 11.14% of the company’s stock.

About PolarityTE (Get Rating)

PolarityTE, Inc, a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services.

See Also

Get a free copy of the Zacks research report on PolarityTE (PTE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for PolarityTE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolarityTE and related companies with MarketBeat.com's FREE daily email newsletter.